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OBJECTIVE: To evaluate the effects of sildenafil on the autonomic nervous system in patients with severe obstructive sleep apnea.
METHODS: Thirteen male patients with severe obstructive sleep apnea (mean age 43±10 years with a mean body mass index 
of 26.7±1.9 kg/m2) received a single 50-mg dose of sildenafil or a placebo at bedtime. All-night polysomnography and heart rate 
variability were recorded. Frequency domain analysis of heart rate variability was performed for the central five-minute sample 
of the longest uninterrupted interval of slow wave and rapid eye movement sleep, as well as for one-minute samples during apnea 
and during slow wave and rapid eye movement sleep after resumption of respiration. 
RESULTS: Compared to the placebo, sildenafil was associated with an increase in the normalized high-frequency (HF
nu
) compo-
nents and a decrease in the low/high-frequency components of the heart rate variability ratio (LF/HF) in slow wave sleep (p<0.01 
for both). Differences in heart rate variability parameters between one-minute post-apnea and apnea samples (D= difference be-
tween resumption of respiration and apnea) were assessed. A trend toward a decreasing magnitude of DLF activity was observed 
during rapid eye movement sleep with sildenafil in comparison to placebo (p=0.046). Additionally, D LF/HF in SWS and rapid eye 
movement sleep was correlated with mean desaturation (sR= -0.72 and -0.51, respectively, p= 0.01 for both), and D HFnu in rapid 
eye movement sleep was correlated with mean desaturation (sR= 0.66, p= 0.02) and the desaturation index (sR= 0.58, p = 0.047).
CONCLUSIONS: The decrease in arousal response to apnea/hypopnea events along with the increase in HF
nu
 components and 
decrease in LH/HF components of the heart rate variability ratio during slow wave sleep suggest that, in addition to worsening sleep 
apnea, sildenafil has potentially immediate cardiac effects in patients with severe obstructive sleep apnea.
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INTRODUCTION
Obstructive sleep apnea (OSA) is associated with a 
number of conditions prevalent among middle-aged men1-4 
and is a major factor contributing to erectile dysfunction.5 
Concerns have arisen about the increasing percentage of men 
using selective phosphodiesterase-5 (PDE-5) inhibitor drugs 
to treat erectile dysfunction.6 Our previous research showed 
that this concern is justified; sildenafil has a magnifying 
effect on respiratory events in patients with severe OSA.7 
Furthermore, OSA remains undiagnosed in 80% of patients.8
Our previous study found that an increase in the number 
and duration of obstructive respiratory events might be 
related to the nasal congestion that is frequently reported 
by sildenafil users.9 These events could also be linked to a 
ventilation-perfusion mismatch10 related to the nitric oxide 
(NO)-dependent vasodilatory effect of sildenafil in the 
absence of ventilation. Although we observed worsening 
apnea and oxyhemoglobin desaturation, our study found an 
interesting less-than-expected increase in arousal.7 
The blunted arousability of OSA patients after sildenafil 
consumption may result from cerebral vasodilation due 
to increased cerebrovascular reactivity to hypercapnia.11 
However, the blunted arousability may also reflect an 
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impaired autonomic nervous system response. 
Research has shown an association between cardiac 
autonomic function measures and the severity of sleep-
disordered breathing.12 Heart rate variability (HRV) is not the 
most direct measure of autonomic activity but is widely used 
because of its non-invasiveness and ease of application.13 In 
patients with OSA, HRV differs in apnea and post-apnea 
periods. The increased negative intrathoracic pressure (the 
Muller maneuver) during respiratory effort arises from 
parasympathetic predominance.14 However, during apnea 
events, a progressive increase in sympathetic activity also 
occurs due to oxyhemoglobin desaturation.15 The maximum 
sympathetic activity occurs at the end of the apnea event; 
from then on, sympathetic activity decreases until the 
recovery of normal respiration.16 A bilateral relationship 
exists between arousal and sympathetic activity in OSA17, 
and both are related to sleep fragmentation. 
To the best of our knowledge, the influence of sildenafil 
on autonomic nervous modulation in patients with severe 
OSA has not yet been reported. The primary goal of the 
present study is to examine this relationship during slow wave 
sleep (SWS) and rapid eye movement (REM). A secondary 
objective is to evaluate sildenafil-induced modifications of 
HRV during apnea and after the resumption of respiration. 
PATIENTS AND METHODS 
Heart rate variability recordings were performed during 
polysomnography (PSG) for the thirteen subjects included 
in our previous study.7 These recordings were evaluated and 
compared with the patients’ PSG respiratory parameters. 
Patients included in the study were between the ages 
of 40 and 65 years and had a body mass index (weight 
in kilograms/height in meters squared) of less than 30, 
an apnea-hypopnea index (AHI) of more than 30 events/
hour of total sleep time (TST), and an oxygen desaturation 
(>4%) index of 10 or more/hour of TST, as evidenced by 
polysomnography performed less than six months earlier. 
Exclusion criteria included daytime hypoxemia, 
concomitant significant debilitating illness, the use 
of nitrates or drugs that could influence sleep, current 
alcohol or drug abuse, and a current or previous habit of 
smoking more than 10 cigarettes a day. Further exclusion 
criteria included acute or chronic respiratory disease 
based on symptoms and respiratory function test results, 
systemic arterial hypertension, and evidence of previous 
or present cardiac disease based on symptoms, 12-lead 
electrocardiography, or Doppler echocardiography. Subjects 
who participated in trials with continuous positive airway 
pressure devices in the previous six months were also 
eliminated from the study.7 
The study protocol was approved by the local Ethics 
Review Committee, and all participants signed written 
informed consent forms. 
Study design
After consenting to participate in the study, all of the 
patients were evaluated for the presence of vascular or 
metabolic disease (i.e., arterial hypertension, diabetes, 
coronary artery disease, cerebrovascular disease, hyper-
choles terolemia, and diabetes mellitus) and smoking 
habits. To exclude patients with cardiac and pulmonary 
hypertension (defined as a pulmonary arterial pressure 
above 20 mmHg) and other respiratory diseases, electrocar-
diography, Doppler echocardiography, and respiratory 
function tests were performed. 
Polysomnography recordings were carried out after a 
night of adaptation to the sleep laboratory. Each participant 
received two coded envelopes, one containing the drug and 
the other containing the placebo, and was asked to randomly 
select one of the envelopes and take the pill that was 
inside at bedtime. The pill in the remaining envelope was 
administered on the next recording night. The codes were 
opened at the end of the study. 
Polysomnography
Bedtime was based on each patient’s habits. At least 
seven hours of recording time were obtained. The following 
measurements were collected: an electroencephalogram (at 
positions C3-A2, C4-A1, and O1-A2 of the International 
10-20 System), a bilateral electrooculogram, a submental 
electromyogram, and an electrocardiogram (modified V2 
lead). 
Respiration was monitored as follows: airflow was 
measured with a nasal cannula/pressure transducer system 
(Pro-Tech Services Inc; Mukilteo, WA, USA) and a mouth 
thermocouple; chest and abdominal efforts were measured 
with uncalibrated, inductive, respiratory plethysmographic 
belts; arterial oxygen saturation (SaO2) was measured with 
pulse oximetry (Ohmeda Hatfield, Herts., England), and 
body position movements were measured with a mercury 
gauge. Body position was determined by a sensor. Data were 
collected using a 16-channel computerized sleep system 
(Harmonie 5.2; Stellate Systems Inc., Montreal, Quebec) 
with a sampling rate of 512 Hz. 
An experienced researcher, blinded to the medication 
condition of the participants, performed the sleep scoring 
of each patient’s three PSGs; the scoring was conducted 
according to previously established parameters.18 Total sleep 
time (TST) was defined as the time elapsed between the first 
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and last recorded epoch of sleep, excluding wakefulness. 
Arousals lasting more than 3 seconds were scored according 
to the criteria established by the American Sleep Disorders 
Association.19
According to the parameters established by the Taskforce 
of the American Academy of Sleep Medicine,20 apnea was 
defined as a period of breathing cessation and hypopnea, 
as a 50% reduction in breathing, or as less than a 50% 
reduction in breathing associated with a 4% desaturation 
of oxyhemoglobin or arousal. The minimum duration of 
an event was ten seconds. The apnea hypopnea index was 
defined as the total number of apneas and hypopneas/hour 
of TST. Obstructive AHI was defined as the number of 
obstructive apneas plus hypopneas/hours of TST, mixed 
AHI was defined as mixed apneas plus hypopneas/hours 
of TST, and central AHI was defined as central apneas plus 
hypopneas/hours of TST. The percentage of TST spent 
in apnea/hypopnea events (%TST AH) was calculated to 
estimate the duration of respiratory events during sleep. 
The desaturation index (DI) corresponded to the number of 
arterial oxygen desaturations (with a drop greater than 4%) 
per hour of TST. The percentage of TST spent with less 
than 90% oxyhemoglobin saturation (Sat O2<90%) was also 
measured.
Heart rate variability
Frequency domain analysis of HRV21 was performed 
for the central five-minute sample of the longest interval of 
SWS and REM sleep that was free of stage shifts, artifacts 
or arousals.22 Additional frequency domain analysis of HRV 
was carried out in one-minute samples during apnea and 
after the opening of the upper airway in SWS and REM. 
Samples during an apnea event were eligible only if they 
occurred during obstructive events and were followed by a 
post-apnea one-minute period that was free of further apnea 
or artifact events. The interval corresponding to the opening 
of the airway was excluded.23 The spectra of the selected 
samples were adjusted for respiration using the Welch 
method with 128-sample Hanning windowing.24 
This study focused on the low frequency band (LF: 0.04 
to 0.15 Hz), which is influenced by sympathetic activity, 
and on the high frequency component (HF: 0.15 to 0.40 
Hz), which is under vagal control, is synchronous with 
respiratory frequency, and represents vagal heart activity.13 
The LF/HF ratio reflects sympathovagal modulation.25 
Normalized (
nu
) values and spectral analysis were used to 
quantify changes in the components of HRV. This method is 
more sensitive to fluctuations in cardiac autonomic influence 
than time domain indexes of HRV because the spectral 
measures are normalized (
nu
) in relation to total power 
(e.g., LF
nu 
= LF/total power and HF
nu
= HF/total power).26 
The power density in the very low frequency range (VLF: 
0.0033 to 0.04 Hz) was not analyzed because short-term 
HRV analysis cannot detect this component. Because the 
total frequency (TF) includes the sum of very low, low, and 
high frequency power, TF values were also not included in 
this analysis.21
Statistical analysis
A Shapiro-Wilk test was used to examine the normality 
of the distribution, and values were expressed as mean ± 
standard error (SE) (Table 1). The differences among groups 
were analyzed using a dependent sample t-test or Wilcoxon 
test. Differences in HRV parameters between one-minute 
post-apnea and apnea periods (D= difference between post-
apnea and apnea) were assessed. In addition, a Spearman 
test was used to determine correlations between DHRV 
parameters and the following respiratory variables: mean 
desaturation of oxyhemoglobin, AHI, DI and respiratory 
arousal index. Statistical evaluations were conducted with 
Statistica (version 6.0) for Windows software (Statsoft, Inc., 
Tulsa, OK, 2004). Significance was established at p<0. 05. 
RESULTS
Table 1 shows the effects of sildenafil and the placebo 
on HRV and respiratory parameters during SWS and REM 
sleep. As described in our previous study,7 we observed 
an increase in mean desaturation (p= 0.02), in the apnea 
hypopnea index (p= 0.0006), and in the desaturation index 
(p=0.002) as well as a decrease in mean saturation (p=0.01) 
after sildenafil treatment in comparison to the placebo. An 
increase in HF (p=0.0001) and a decrease in LF/HF in SWS 
sleep (p=0.002) were also observed after sildenafil treatment. 
The respiratory arousal index did not significantly differ in 
relation to the treatments, but a decrease in SWS, in terms 
of both minutes and percentage of TST, was observed after 
sildenafil. 
A decreased magnitude of the difference (D) in the 
LF component of HRV was observed in REM sleep after 
sildenafil treatment in comparison to the placebo (p=0.046). 
A clear trend toward a decrease in D LF/HF was also 
observed in REM sleep after sildenafil (Figure 1).
Examinations of the correlations between HRV and 
respiratory parameters showed that D LF/HF in SWS and 
REM sleep was correlated with mean desaturation (sR = 
-0.72 and -0.51, respectively, p = 0.01 for both), whereas 
D HF in REM sleep was correlated with mean desaturation 
(sR=0.66, p = 0.02) and the desaturation index (sR = 0.58, p 
= 0.047).
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DISCUSSION
This double-blind, cross-over, placebo-controlled study 
builds on data from our previous research on the respiratory 
effects of sildenafil in 13 patients with severe OSA.7 The 
present study examined the impact of sildenafil on HRV 
during SWS and REM sleep as well as differences in HRV 
between apnea and respiration resumption. We used short-
term frequency domain analysis throughout the sleeping 
period and paid special attention to high-frequency and 
low-frequency ranges. 
Our previous study found that sildenafil was correlated 
with impaired respiratory parameters during sleep (e.g., 
mean values of saturation, desaturation, apnea hypopnea 
index and desaturation index) that were not followed by an 
increase in the respiratory arousal index.7 This study found 
that sildenafil was correlated with an increase in HF
nu
 and a 
decrease in the LF/HF components of HRV during SWS but 
not during REM sleep. We examined the mean difference in 
HRV parameters (D) between post-apnea and apnea events 
and identified a trend toward a reduced modification of LF
nu
 
and of the LF/HF components of HRV during REM sleep 
with sildenafil in comparison to the placebo. 
These findings suggest that, in patients with severe 
OSA, a single dose of sildenafil (50 mg) before sleep affects 
sleep HRV, with predominance of parasympathetic upon 
sympathetic tone. This was evident in SWS, but not in 
REM, in which greater sympathetic tone typically occurs.12 
Furthermore, the trend toward less modification of LF
nu
 and 
of the LF/HF components of HRV during REM sleep with 
sildenafil suggests that either the increased LF overshadows 
the HF increment in this sleep stage or that a ceiling effect 
occurs in the sympathetic tone that is related to the severity 
of respiratory events.12, 15, 16
In the evaluation of post-apnea and apnea modification 
in HRV, the first open breath was excluded because of the 
typical surge of sympathetic activity triggered by hypoxia or 
by the activation of carotid and/or aortic chemoreceptors.27 
As found in previous studies (see Younes27 for reviews), 
the amplitude of the modification of HRV parameters had 
relatively little influence on the number of apnea events in 
these patients. 
This research is clinically important because abnormal 
autonomic control is a key factor in the causal link between 
OSA and cardiovascular disease.14,16 Apnea is associated with 
increased circulating norepinephrine and with the loss of 
vagal tone, a combination that may underlie life-threatening 
arrhythmias.28 Long-term complications, i.e., hypertension, 
myocardial infarction, and stroke, may result from repeated 
temporary loss of NO in tissues. This loss of NO is produced 
by a lack of oxygen, one of the two essential substrates of 
NO.10 Manipulation of the NO/cyclic GMP system may 
therefore be a therapeutic option in this circumstance. Our 
finding that the HF component of HRV increases in severe 
OSA patients after the use of sildenafil shows that caution 
must be exercised when changes in HRV spectral indices 
Table 1 - Analysis of heart rate variability in slow wave sleep and REM sleep. Respiratory sleep parameters after placebo 
and sildenafil.
Sleep parameter Placebo Sildenafil p
SWS LF 0.74 (0.04) § 0.72 (0.03) 0.81
HF 0.12 (0.02) 0.28 (0.03) 0.0001
LF/HF 10.14 (2.29) § 3.57 (0.62) 0.002
SWS min
        %TST
77.0 (7.3)
17.1 (1.4)
53.3 (4.4)
12.5 (0.9)
0.001
0.001
Respiratory arousal index 0.5 (0.2) 0.7 (0.2) § 0.16
REM LF 0.75 (0.04) 0.74 (0.04) 0.89
HF 0.25 (0.04) 0.26 (0.04) 0.89
LF/HF 5.33 (1.05) 5.09 (1.29) § 0.92
REM min
      %TST
90.1 (8.4)
20.3 (1.5)
91.1 (5.8)
21.3 (1.1)
0.89
0.38
Respiratory arousal index 17.3 (1.9) 18.2 (1.9) § 0.22
Respiratory data Saturation (mean) 93.8 (0.4) 92.1 (0.5) 0.01
Desaturation (mean) 8 (1.3) § 9.9 (1.3)  § 0.02
Apnea hypopnea index 32.3 (3.1) 48.0 (5.7)  § 0.0006
Desaturation index 18.5 (2.5) 30.3 (4.0)  § 0.002
Mean (standard error). § Data with nonparametric distribution. Heart rate variability was analyzed in the central five-minute sample of the longest interval 
of slow wave sleep (SWS) and REM sleep that was free of stage shifts, artifacts or arousals.
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are interpreted to represent changes in vagal or sympathetic 
activities.29 Sometimes, estimates of HF do reflect heart 
rate variability;30 instead, they reflect both non-respiratory 
sinus arrhythmia and respiratory instability. The emergence 
of hyperpneic breaths following the termination of apnea 
can increase estimates of HF, leading to the erroneous 
interpretation of increased vagal tone during these episodes.31
The influence of sleep stage on respiration and HRV 
has been reviewed in detail.12 The shift from wakefulness to 
non-REM sleep is accompanied by a progressive increase in 
parasympathetic modulation and a decrease in sympathetic 
modulation of the heart rate. On the other hand, REM sleep, 
which typically occurs at 90-minute intervals, is associated 
with significantly greater sympathetic modulation than non-
REM sleep. In addition, ventilation and breathing patterns 
vary according to sleep stage; non-uniform ventilatory 
patterns can substantially influence LF and HF, particularly 
in sleep-disordered breathing conditions. High-frequency 
power is closely associated with the respiratory modulation 
of heart rate, commonly known as respiratory sinus 
arrhythmia. Both tidal volume and breathing frequency 
compromise the reliability of the HF component of HRV as 
a measure of parasympathetic activity.31 
Clinically, OSA is a REM-sleep related disease; 
obstructive events occur more frequently, for a longer 
duration of time, and with more desaturation of 
oxyhemoglobin during REM sleep than non-REM sleep.32 
Variable surges in sympathetic activity are associated with 
a range of arousal events. Arousals can vary from increases 
in muscular and respiratory activity to sleep stage shifts and 
full awakening.33 Changes at the cortical level may not be 
visible in SWS because the magnitude of the autonomic 
activation is lower than in light and REM sleep. Previous 
studies reported that around 30% of apneas/hypopneas, 
particularly in NREM sleep, are not terminated by visible 
cortical arousals.34 The present study provides evidence 
that, after administration of sildenafil, either hypoxemia or 
increased upper airway resistance due to nasal congestion 
may lead to a lack of arousals during SWS as a response 
to apneas and hypopneas. The same was not observed 
in REM sleep due to eased sympatho-vagal balance and 
arousability.35 Exacerbation of obstruction and an increase 
in inspiratory effort make upper airway pressure even more 
negative. An ineffective pharyngeal dilator reflex may also 
impair arousal and lead to central apnea events in OSA.28
It is also possible that the profound change in respiratory 
pattern observed in the cases of severe OSA in this 
study may have had a direct influence on the excitatory 
drive of peripheral and central chemoreceptors after 
sildenafil administration. In addition to a direct effect on 
chemoreceptor afferent input, an indirect action at the level 
of central respiratory drive may profoundly influence vagal 
efferent activity.36 The predominant cholinergic control of 
airway smooth muscle at the level of the neuro-effector 
junction has recently been reviewed in detail by Jordan36 
and the anatomical organization of airway pathways in the 
brainstem has been reviewed by Mazzone and Canning.37The 
data presented in this study also raise important questions 
Figure 1 - Modification of HRV parameters in post apnea and apnea events.
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about the role of NO in the responsiveness of the cerebral 
vasculature to changes in blood gas tension as well as 
to sildenafil. NO plays a direct role in obstructive apnea 
events; during these events, there is an intermittent failure 
to transport nasal NO to the lungs with each breath and 
a decrease in NO synthesis due to the lack of oxygen.38 
In this context, sildenafil, a PDE-5 inhibitor, potentially 
impairs NO-dependent protective mechanisms of adaptation 
to intermittent hypoxia. For example, it may affect the 
compensatory mechanism that matches perfusion to 
ventilation and alter efferent pathways that control the 
activity of pharyngeal dilators and thoracic musculature.10, 39
Furthermore, neuronal and endothelial NO exerts 
an inhibitory nitrergic influence on both inotropic and 
chronotropic cardiac responses to adrenergic stimulation.40 
NO acts to increase acetylcholine release in cholinergic 
neurons. Conversely, NO generated in the sympathetic 
ganglia reduces the release of noradrenaline.41 
The results of our study are also supported by the 
findings of Chowdhary et al.,42 which demonstrated that 
enhancement of baroreflex gain by NO may underlie the 
modulation of cardiac vagal control. An increase in HF, but 
not in LF, was observed with NO-synthetase drug inhibitors 
and exogenous NO donors.
In addition to the reported involvement of NO in sleep 
termination, other studies have reported that NO43 has a 
somnogenic effect in OSA patients (see Gautier-Sauvigné44 
for a review of this literature). These studies support our 
finding that the use of sildenafil is associated with blunted 
arousal response to respiratory events during sleep. 
Our data on the modification of HRV components 
between post-apnea and apnea events are heterogeneous; 
this may highlight the individual pattern of collapsibility of 
the upper airway and of ventilatory instability. The degree 
of airway collapsibility and the necessary effort required to 
open it are inversely proportional to and dependent on the 
degree of arousal.45 
Several methodological considerations must be 
acknowledged. These include the application of HRV 
analysis to non-stationary conditions such as sleep in OSA 
patients. To overcome this difficulty, we used spectral 
analysis of central 5-minute samples of the longest interval 
of SWS and REM sleep that was free of stage shifts, artifacts 
or arousals.23 However, because AHI was high, particularly 
after the use of sildenafil, it was not possible to obtain five-
minute samples of SWS or REM sleep that were free of 
apnea or hypopnea events; adjustments for respiration were 
performed in the spectra of the selected samples.24
This study has several limitations. First, we estimated 
changes in heart frequency using HRV rather than 
baroreceptor reactivity. However, it was not feasible to 
perform recordings of baroreflex or vagal efferent activity 
which are supposedly impaired during sleep in severe OSA 
patients. Second, overnight measures of CO2 and the number 
of central sleep apnea events would provide additional 
information regarding chemoreceptor influence on HRV 
parameters. Third, sildenafil is designed to influence penile 
erection for 2 to 5 hours; this is less time than a full night 
of sleep. However, little is known about the duration of the 
other effects of this drug. Further studies of long-term PDE-5 
inhibitors such as vardenafil and of daily sildenafil doses are 
needed to improve our understanding of this group of drugs. 
Finally, the small sample size of this study raises questions 
about the applicability of results. The data from the 13 
patients, however, show a consistently low ratio of arousals 
and apnea/hypopnea events during SWS and REM sleep, as 
well as increased desaturation and lower saturation after the 
use of sildenafil. Additionally, because all eligible recorded 
apneas/hypopneas were similarly analyzed, the large amount 
of data may be representative of the characteristics of the 
respiratory events.
The lack of increase in the arousal index during SWS 
may suggest a link between the worsening of OSA and 
HRV abnormalities after sildenafil. These findings provide 
evidence of a potential risk of sildenafil use by OSA patients 
with cardiovascular disease. Our data support Stein et al.’s 
suggestion that increases in HF estimates do not always 
reflect better heart rate variability.30 
In conclusion, the decrease in arousal response to apnea/
hypopnea events along with the increase in HF and decrease 
in LH/HF components of heart rate variability during SWS 
suggest that, in addition to worsening sleep apnea, sildenafil 
has potentially immediate cardiac effects in patients with 
severe obstructive sleep apnea.
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